PBYI - Puma Biotechnology reports Q4 results provides Q1 FY 2023 guidance
- Puma Biotechnology press release ( NASDAQ: PBYI ): Q4 Non-GAAP EPS of -$0.07.
- Revenue of $65.7M (+18.6% Y/Y) beats by $8.64M .
- Sees Q1 2023 net product revenue of $43M to $46M, royalty revenue of $4M to $6M.
- Sees FY 2023 net product revenue of $205M to $210M, royalty revenue of $25M to $30M.
For further details see:
Puma Biotechnology reports Q4 results, provides Q1, FY 2023 guidance